Literature DB >> 17652764

Regulation of igf-I signaling in retinal endothelial cells by hyperglycemia.

Emily C Miller1, Byron E Capps, Ravi R Sanghani, David R Clemmons, Laura A Maile.   

Abstract

PURPOSE: To investigate the role of hyperglycemia in regulating the proliferative response of retinal endothelial cells (RECs) to insulin-like growth factor (IGF)-I.
METHODS: The regulation of IGF-I signaling by glucose concentration was assessed by biochemical analysis of primary RECs grown in media containing normal (5 mM) and high (25 mM) glucose. Cell counting was used to asses the proliferative response to IGF-I.
RESULTS: Glucose (25 mM) enhanced the proliferative response of RECs to IGF-I. Phosphorylation of the adaptor protein Shc (Src homology 2 domain containing) transforming protein 1) was increased in RECs grown in high glucose. For Shc to be phosphorylated, it must be recruited to the cytoplasmic domain of the transmembrane protein SHPS-1 (SHP substrate-1). Shc recruitment to SHPS-1 was increased when RECs were grown in high glucose. The difference in Shc recruitment to SHPS-1 was attributable to a difference in SHPS-1 phosphorylation that is required for Shc recruitment. This, in turn, was attributable to an increase in SHPS-1 association with integrin-associated protein (IAP), which is necessary for SHPS-1 phosphorylation. The difference in response under the two different glucose conditions appeared to be attributable to changes in the activation of the integrin alphaVbeta3, since blocking alphaVbeta3 in high glucose inhibited the response to IGF-I, whereas addition of the active region of vitronectin to RECs grown in normal glucose enhanced their response.
CONCLUSIONS: This study demonstrates that hyperglycemic conditions enhance the response of RECs to IGF-I by increasing the association of IAP with SHPS-1 permitting the formation of the SHPS-1-Shc signaling complex, which is required for the proliferative response to IGF-I.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652764     DOI: 10.1167/iovs.07-0014

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Expression of integrins in human proliferative diabetic retinopathy membranes.

Authors:  Allison Ning; Jing Cui; David Maberley; Patrick Ma; Joanne Matsubara
Journal:  Can J Ophthalmol       Date:  2008-12       Impact factor: 1.882

Review 2.  Resveratrol and the eye: activity and molecular mechanisms.

Authors:  Christina Bola; Hannah Bartlett; Frank Eperjesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-21       Impact factor: 3.117

3.  Managing diabetic macular edema: The leading cause of diabetes blindness.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2011-06-15

4.  Endothelial nitric oxide synthase activation is required for heparin receptor effects on vascular smooth muscle cells.

Authors:  Yaqiu Li; Leanna M Talotta-Altenburg; Kayli A Silimperi; Grace O Ciabattoni; Linda J Lowe-Krentz
Journal:  Am J Physiol Cell Physiol       Date:  2019-12-31       Impact factor: 4.249

5.  Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes.

Authors:  L A Maile; K Gollahon; C Wai; G Byfield; M E Hartnett; D Clemmons
Journal:  Diabetologia       Date:  2011-12-23       Impact factor: 10.122

6.  Identification of compounds that inhibit IGF-I signaling in hyperglycemia.

Authors:  Laura A Maile; Lee B Allen; Umadevi Veluvolu; Byron E Capps; Walker H Busby; Michael Rowland; David R Clemmons
Journal:  Exp Diabetes Res       Date:  2010-01-06

7.  Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

Authors:  Laura A Maile; Walker H Busby; Katherine A Gollahon; William Flowers; Nikol Garbacik; Stefani Garbacik; Kara Stewart; Timothy Nichols; Dwight Bellinger; Amit Patel; Paul Dunbar; Matt Medlin; David Clemmons
Journal:  Endocrinology       Date:  2014-08-29       Impact factor: 4.736

Review 8.  Models of retinal diseases and their applicability in drug discovery.

Authors:  Goldis Malek; Julia Busik; Maria B Grant; Mayur Choudhary
Journal:  Expert Opin Drug Discov       Date:  2018-01-30       Impact factor: 6.098

9.  p66shc inhibits insulin-like growth factor-I signaling via direct binding to Src through its polyproline and Src homology 2 domains, resulting in impairment of Src kinase activation.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

Review 10.  An ocular view of the IGF-IGFBP system.

Authors:  Dung V Nguyen; Sergio Li Calzi; Lynn C Shaw; Jennifer L Kielczewski; Hannah E Korah; Maria B Grant
Journal:  Growth Horm IGF Res       Date:  2013-04-08       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.